Division of Hematology and Oncology

Study identifies critical regulator of tumor-specific T cell differentiation

A study published June 17 in Nature offers clues as to why blocking inhibitory receptors on tumor-infiltrating T cells may not always work

Eng named to GI cancer leadership position at VICC

Cathy Eng, MD, a national and international leader in gastrointestinal medical oncology, is joining Vanderbilt-Ingram Cancer Center (VICC).

From left, Benjamin Brown, Christine Lovly, MD, PhD, Yun-Kai Zhang, PhD, Jens Meiler, PhD, and colleagues are exploring new ways to understand resistance to targeted cancer therapy drugs.

Study reframes approach to targeted therapy resistance

When a tumor mutates and develops resistance to a targeted therapy, researchers often focus on the acquisition of new mutations within the drug target as they seek an alternative treatment, but a team of Vanderbilt scientists has shown this may not be sufficient.

Longtime colleagues and friends Curt Thorne, left, and Terry Burke enjoyed sailing together.

Bladder cancer research fund honors mentor’s lasting influence

The Terry Burke Fund for Bladder Cancer Research at Vanderbilt-Ingram Cancer Center is supporting a range of discovery research aimed at improving outcomes for bladder cancer patients, and it is helping train the next generation of bladder cancer physician-scientists.

Investigators map genomic landscape of very rare cancer

A team of Vanderbilt researchers mapped out the genomic landscape of a metastatic malignant proliferating tricholemmal tumor and identified a targeted treatment for this very rare cancer.

Grant supports novel imaging initiative to enhance cancer care

A Vanderbilt initiative to develop predictive imaging technologies that clinicians can use to better match patients with personalized care has received National Cancer Institute (NCI) funding.

1 8 9 10 11 12 16